Aqueous Cannabinoid Solution Stability and Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid formulations, such as soft gelatin capsule dronabinol, are unstable at room temperature and exhibit high inter-subject variability in in vivo absorption, leading to inconsistent therapeutic effects.
Innovation Solution
An aqueous-based oral cannabinoid solution comprising water, alcohol, and propylene glycol, with specific ratios of these components, is developed to enhance stability and absorption profile, including the use of stabilizers like butylated hydroxyanisole and polyethylene glycol, to maintain dronabinol levels and reduce variability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soft gelatin capsule formulations are used, then cannabinoid delivery is achieved, but stability at room temperature deteriorates and inter-subject variability increases
Solution Approach 1:
The patent changes the physical and chemical parameters of the formulation by transitioning from soft gelatin capsules to an aqueous-based liquid solution with specific compositional ratios (water: 5-40%, alcohol: 60-80%, propylene glycol: 1-20%). This parameter change enables room temperature stability while reducing inter-subject variability in absorption, directly resolving the technical contradiction between reliability and formulation complexity.
2Reliability
If aqueous-based formulations are used, then stability improves, but in vivo absorption variability increases
Solution Approach 1:
The patent employs a composite formulation system combining water, alcohol, and propylene glycol in specific ratios, along with stabilizers (0.01-0.1% BHA or BHT) and solubilizers (0.1-10% surfactants). This composite material approach maintains room temperature stability while ensuring consistent in vivo absorption by addressing both stability and absorption precision simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides a stable cannabinoid formulation that maintains dronabinol levels within 90-110% for at least 18 months, offering faster onset and lower inter-subject variability in in vivo absorption compared to traditional soft gelatin capsules, ensuring consistent therapeutic effects.
Implementation Method 1
an aqueous-based oral cannabinoid solution comprising water, alcohol and propylene glycol
Implementation Method 2
the use of stabilizers like butylated hydroxyanisole and polyethylene glycol, to maintain dronabinol levels
Data Source
AI summary
Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.